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Background: This study aimed to compare the changes in kidney function and the association of tumor size and
renal outcomes between patients with renal cell carcinoma (RCC) who underwent radical nephrectomy (RN) and
those who underwent partial nephrectomy (PN).
Methods: A retrospective cohort study was conducted for 557 patients with an RCC of ≤7 cm in diameter and
normal contralateral kidney function who underwent PN or RN. PN was performed for 218 (39%) patients. Renal
outcomes included the incidence of acute kidney injury (AKI), new-onset chronic kidney disease (CKD), and a ≥25%
decline in eGFR 1 year after surgery.
Results: Serial changes in eGFR were compared during the 3 years of follow-up. Postoperative eGFR was
significantly lower in patients undergoing RN than in those undergoing PN. The incidence of AKI and new-onset
CKD was significantly higher in patients after RN (70.1% vs. 24.3%, respectively; P <0.001) than after PN (55.7% vs.
6.2%, respectively; P <0.001). According to the multivariable logistic regression analysis, RN was an independent risk
factor for a ≥25% decline in kidney function after 1 year regardless of the tumor size, even after adjusting for
various covariates.
Conclusions: Compared to PN, RN for even a moderate sized RCC leads to an increased incidence of AKI and
new-onset CKD, and is a significant risk factor for kidney function decline. Therefore, PN should be considered as
the choice of surgical treatment for RCCs that are ≤7 cm in diameter in order to preserve renal function postoperatively.
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Kidney cancer is the 13th most common malignancy
worldwide and ranks 3rd among the leading causes of
genitourinary cancers in Korea [1]. Renal cell carcinoma
(RCC) accounts for approximately 90% of all renal ma-
lignancies. Although the incidence of RCC is declining
in some European countries in recent years, a world-
wide increase in RCC has been observed during the last
decade [2].
Recently, the development and widespread use of im-
aging technologies have led to a decrease in the size and
stage migration of newly detected renal cortical tumors. In
the last two decades, increased detection of small renal
masses has led to a greater utilization of partial nephrec-
tomy (PN). In patients with small renal cortical tumors,* Correspondence: skimw@chonnam.ac.kr
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unless otherwise stated.radical nephrectomy (RN) is a significantly independent
risk factor for the development of chronic kidney disease
(CKD) than PN [3,4]. Preserving the renal parenchyma by
PN should be considered in most patients with small renal
tumors because the decreased kidney function following
RN might increase the risk for cardiovascular events and
overall mortality in the long-term [5-7]. Although it has
been shown that the development of CKD or decreased
kidney function is higher in patients with RCC after RN
than PN [8,9], the renal outcomes between RN and PN
are not well-understood in these patients. In addition, re-
searchers of a recent study demonstrated that the inci-
dence of CKD increased as the renal cortical tumor size
decreased following RN [10]. However, data on the
changes of kidney function after RN or PN in patients
with renal tumors >4 cm are currently limited [11,12].
We hypothesized that RN influences the risk for delete-
rious renal outcomes for acute or chronic state patients. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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was to compare the changes in kidney function and various
renal outcomes as well as the association of tumor size and
renal outcomes between patients with RCC undergoing RN
and those undergoing PN. We hope that the findings of this
study will help enhance surgical treatment and improve
clinical outcomes for patients with RCC.
Methods
Study design and patient population
The electronic medical records were reviewed for all
adult patients undergoing RN or PN for kidney cancer
between December 2003 and December 2012 at the
Chonnam National University Hospital. Among the 916
patients identified, we excluded patients with bilateral
tumors and benign renal masses (n = 263), end-stage renal
disease (patients with a history of hemodialysis, peritoneal
dialysis, or kidney transplantation; n = 12), an estimated
glomerular filtration rate (eGFR) <15 mL/min/1.73 m2
(n = 1), a RCC >7 cm in diameter (n = 82), and those who
had a nephrectomy for metastatic RCC (n = 1). A total of
557 patients were included in the final analysis. RN was
conducted in patients with a tumor involving a more cen-
tral position of the kidney, suspected lymph node involve-
ment, and multiple tumors in a single kidney. Patients
with a tumor of <7 cm in size underwent a PN when it
was technically feasible. Otherwise, the surgical modality
was chosen at the discretion of the surgeon. Cases of
death were ascertained by data linkage of the national
death certificate database of Statistics Korea and the re-
gional cancer registries. The waiver of informed patient
consent and approval of the study protocol were obtained
by the Institutional Review Board of Chonnam National
University Hospital in 2014. This study was conducted ac-
cording to the principles of the Declaration of Helsinki.
Data collection and definition
Laboratory data regarding the levels of serum creatinine
(SCr), hemoglobin, and urine protein were obtained
from the medical records and reviewed by a trained
study coordinator. SCr levels were measured at 6 time
points (i.e., preoperatively, at 7 days, during discharge,
and 3 months, 1 year, and 3 years after nephrectomy).
Tumor stage was reassessed according to the American
Joint Committee on Cancer and the International Union
for Cancer Control tumor-node-metastasis classification
[13]. The Fuhrman grading system was used to measure
nuclear grades [14]. To identify the impact of the type of
surgery on renal outcomes according to the tumor size,
we divided the patients into the following 2 groups: (1)
tumor size ≤4 cm and (2) 4 cm < tumor size ≤7 cm.
Acute kidney injury (AKI) was defined according to
the Kidney Disease Improving Global Outcomes clinical
practice guidelines. According to these guidelines, AKIis present when an abrupt reduction in kidney func-
tion results in an absolute increase in the SCr level
by ≥0.3 mg/dL within 48 hours, a known or pre-
sumed ≥1.5-fold increase in the baseline SCr level
within the prior 7 days, or a reduction in urine out-
put (<0.5 mL/kg/h) for 6 hours [15]. We did not con-
sider the urine output criteria because retrospectively
collected data can be inaccurate in this regard. AKI
was further classified into the following 3 stages ac-
cording to the severity of kidney injury: AKI stage 1,
increase in the SCr level by ≥0.3 mg/dL or 1.5–1.9
times baseline; AKI stage 2, increase in the SCr level
by 2.0–2.9 times baseline; and AKI stage 3, increase
in the SCr level by ≥4.0 mg/dL or ≥3.0 times baseline
or initiation of renal replacement therapy. The pa-
tients who met the AKI criteria were further classi-
fied into the transient AKI (normalization of SCr
level at discharge; SCr level ≤1.3 mg/dL) and the persistent
AKI (sustained elevation of SCr level at discharge; SCr
level >1.3 mg/dL) groups.
New-onset CKD was defined as a decrease in the
eGFR to <60 mL/min/1.73 m2 3 months after nephrec-
tomy in patients with a preoperative eGFR >60 mL/min/
1.73 m2.
Assessment of renal function
SCr levels were analyzed by the Jaffe method, which was
calibrated by isotope dilution mass spectrometry. The
eGFR (units = mL/min/1.73 m2) was calculated using the
Chronic Kidney Disease Epidemiology Collaboration
equation as follows: 141 ×minimum (creatinine/κ, 1)α ×
maximum (creatinine/κ, 1)-1.209 × 0.993age × 1.018 (if fe-
male) × 1.159 (if black), where κ is 0.7 for women and
0.9 for men, and α is −0.329 for women and −0.411 for
men [16].
Statistical analysis
Continuous variables were presented as mean ± standard
deviation and categorical variables were expressed as the
number and percentage of patients. Comparative ana-
lysis was performed using Student’s t-test for continuous
variables and Pearson chi-square test for categorical var-
iables. An analysis of covariance and multiple logistic
regressions adjusted to age, sex, and proteinuria were
performed to evaluate the changes in eGFR and renal
outcomes (including AKI, new-onset CKD, and a ≥25%
decline in eGFR after 1 year) between RN and PN at
various time points. We performed a two-way analysis of
variance (ANOVA) with repeated measures to compare
the mean changes of eGFR over time between RN and
PN according to tumor size. Within-group comparisons
for eGFR at 7 days, 3 months, and 3 years were performed
using a general linear model-ANOVA followed by a
Bonferroni’s correction applied to the post-hoc analysis
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0.017 was considered statistically significant. Multivariable
logistic regression analyses were performed to identify the
independent predictors of adverse renal outcomes accord-
ing to tumor size after nephrectomy. Age, sex, blood pres-
sure (systolic and diastolic), body mass index, history of
smoking, hypertension, and diabetes mellitus, urine pro-
tein levels, type of surgical procedure, and the pathologic
stage were all included in the multivariable logistic regres-
sion analysis. All statistical tests were 2-tailed and P <0.05
was considered significant. The analyses were performed
using the Statistical Package for Social Sciences software,
version 17.0 (SPSS, Chicago, Illinois, USA).
Results
Patient characteristics
A total of 557 patients were included in the retrospective
analysis. The mean age of the patients was 60.7 years,
393 (70.6%) patients were male, and the mean baseline
eGFR was 81.5 ± 16.7 mL/min/1.73 m2. RN and PN were
performed in 339 (61%) and 218 (39%) patients, respect-
ively. The clinical characteristics of the patients with
RCC are listed in Table 1 according to the type of sur-
gery. Compared to patients undergoing RN, those
undergoing PN were more likely to have lower systolicTable 1 Baseline clinical characteristics
All patients (n = 557)
Age (years) 60.7 ± 12.3
Male (%) 393 (70.6)
Systolic blood pressure (mmHg) 132 ± 14
Diastolic blood pressure (mmHg) 83 ± 10
Body mass index (kg/m2) 24.4 ± 3.1
Diabetes (%) 89 (15.9)
Hypertension (%) 220 (39.4)
Coronary artery disease (%) 25 (4.5)
Cerebral vascular disease (%) 15 (2.7)
History of Smoking (%)
Never smoked 342 (61.4)
Ex-smoker 104 (18.7)
Current smoker 111 (19.9)





Baseline creatinine (mg/dL) 0.95 ± 0.23
Baseline eGFRb 81.5 ± 16.7
aDip-stick test.
beGFR (mL/min/1.73 m2) calculated using the Chronic Kidney Disease-Epidemiology
Abbreviations: eGFR estimated glomerular filtration rate, RN radical nephrectomy, Pand diastolic blood pressures (130 ± 14 mmHg and 82 ±
10 mmHg vs. 133 ± 14 mmHg and 84 ± 10 mmHg, re-
spectively) and higher baseline eGFR (83.9 ± 15.1 mL/
min/1.73 m2 vs. 80.1 ± 17.6 mL/min/1.73 m2, respect-
ively). However, there were no differences between the
RN and PN groups for age, sex, body mass index,
hemoglobin levels, degree of urine protein, and a history
of hypertension, diabetes, coronary artery disease, cere-
bral vascular disease, and smoking. Apart from the
tumor size and pathologic stage, there were no signifi-
cant differences in pathological characteristics (including
tumor location, histological subtypes, and Fuhrman
grade) between the RN and PN groups (Table 2). Open
surgery was performed more frequently in the PN group
compared to the RN group (22.9% vs. 13.6%, respect-
ively; P = 0.004). The overall recurrence rate was greater
in the RN group than in the PN group (11.2% vs. 3.2%,
respectively; P = 0.001). However, there was no differ-
ence in recurrence rate at the ipsilateral or contralateral
kidney between the RN and PN groups (4.1% vs. 1.8%,
respectively; P = 0.150).
Changes of renal function after PN or RN
Serial changes in the mean eGFR from before surgery to
the time points following surgery (i.e., 7 days, at discharge,RN (n = 339) PN (n = 218) P value
61.0 ± 12.8 60.3 ± 11.4 0.495
234 (69.0) 159 (72.9) 0.323
133 ± 14 130 ± 14 0.027
84 ± 10 82 ± 10 0.015
24.4 ± 3.1 24.3 ± 3.0 0.748
55 (16.1) 34 (15.7) 0.885
139 (40.8) 81 (37.3) 0.418
13 (3.8) 12 (5.5) 0.339
7 (2.1) 8 (3.7) 0.247
0.061
203 (59.9) 139 (63.8) 0.359
58 (17.1) 46 (21.1) 0.238
78 (23.0) 33 (15.1) 0.023
13.8 ± 1.7 14.1 ± 1.5 0.097
0.124
286 (84.6) 196 (89.9) 0.073
32 (9.5) 19 (8.8) 0.764
20 (5.9) 3 (1.4) 0.008
0.97 ± 0.25 0.93 ± 0.18 0.021
80.1 ± 17.6 83.9 ± 15.1 0.007
Collaboration equation.
N partial nephrectomy.
Table 2 Baseline pathological characteristics
All patients (n = 557) RN (n = 339) PN (n = 218) P value
Surgical approach (%) 0.004
Open 96 (17.2) 46 (13.6) 50 (22.9)
Laparoscopic 461 (82.8) 293 (86.4) 168 (77.1)
Tumor location (%) 0.925
Right 285 (51.2) 174 (51.3) 111 (50.9)
Left 272 (48.8) 165 (48.7) 107 (49.1)
Tumor size (cm) 3.4 ± 1.5 4.1 ± 1.4 2.4 ± 1.0 <0.001
≤ 4, No (%) 370 (66.4) 167 (49.3) 203 (93.1) <0.001
4 < size ≤7, No (%) 187 (33.6) 172 (50.7) 15 (6.9) <0.001
Histology (%) 0.077
Clear cell 439 (79.0) 270 (79.9) 167 (77.5)
Papillary 47 (8.5) 20 (5.9) 27 (12.4)
Chromophobe 43 (7.7) 29 (8.6) 14 (6.5)
Other 27 (4.9) 19 (5.6) 8 (3.7)
Fuhrman grade (%) 0.721
1 68 (12.2) 38 (11.2) 30 (13.8)
2 358 (64.3) 218 (64.3) 140 (64.2)
3 109 (19.6) 67 (19.8) 42 (19.3)
4 12 (2.2) 9 (2.7) 3 (1.4)
Pathologic stage (%)a 0.005
I 546 (98.0) 328 (96.8) 218 (100)
III 11 (2.0) 11 (3.2)
Nephrectomy size (cm) 9.2 ± 4.7 12.5 ± 2.2 3.9 ± 1.5 <0.001
aBased on the tumor node metastasis staging system supported by both the American Joint Committee on Cancer and the International Union for Cancer Control.
Abbreviations: RN radical nephrectomy, PN partial nephrectomy.
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gery (i.e., PN and RN) and tumor size (≤4 cm and 4 cm <
tumor size ≤7 cm) are shown in Figure 1. The eGFR was
significantly lower in patients undergoing RN than in
those undergoing PN 3 years after surgery, even after
adjusting for age and sex (P <0.05), as determined using
two-way ANOVA with repeated measure analysis. The RN
and PN groups, categorized according to tumor size, also
showed similar changes in eGFR after surgery, even
though the baseline eGFR was not different between the 2
groups. The mean eGFR decreased from 80.1 mL/min/
1.73 m2 before surgery to 56.2 mL/min/1.73 m2 at
3 months (P <0.001) and then increased to 59.0 mL/min/
1.73 m2 3 years after RN (P = 0.001). However, there were
no significant changes in eGFR over time (i.e., from sur-
gery to follow-up period) in patients with PN.
Renal outcomes after PN or RN
As shown in Table 3, the incidence of AKI in patients
undergoing RN was significantly higher than patients
undergoing PN (70.1% vs. 24.3%, respectively; P <0.001).
Furthermore, the incidence of transient and persistentAKI was significantly higher in patients undergoing RN
than PN. In addition, compared to the PN group, the
RN group had significantly higher prevalence of new-
onset CKD 3 months after the operation (55.7% vs. 6.2%,
respectively; P <0.001) and a ≥25% decline in the eGFR
after 1 year (65.4% vs. 8.1%, respectively; P <0.001), even
after adjusting for age, sex, and proteinuria. All-cause
mortality was significantly higher in patients undergoing
RN than in those undergoing PN (10.0% vs. 3.7%;
P = 0.006). Among these patients, there was 1 case of
death in a patient undergoing RN, who died due to end-
stage renal disease; no cases of deaths were observed in
the PN group.
We identified independent risk factors for the adverse
renal outcomes that were categorized according to the
tumor size after nephrectomy by using multivariable lo-
gistic regression analysis (Table 4). Among the risk con-
tributors in the total cohort (tumor size ≤7 cm), RN was
found to be the most important factor for the incidence
of AKI, new-onset CKD, and a ≥25% decline in eGFR
after 1 year. Furthermore, compared to patients under-
going PN, those undergoing RN for tumors ≤4 cm and
Figure 1 Serial changes in estimated glomerular filtration rate (eGFR) before and after surgery in patients undergoing radical and
partial nephrectomy in the total cohort (A), and patients with a tumor ≤4 cm (B) or 4–7 cm (C) in size. *P <0.05; vs. eGFR in the radical
nephrectomy group at each time point.
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in eGFR after 1 year after multiple adjustments (odds ra-
tio [OR] = 28.3, 95% confidence interval [CI] = 14.3
56.0, P <0.001; OR = 12.6; 95% CI = 1.45–108.9, P =
0.022, respectively).
Discussion
In this study, we determined that the postoperative
eGFR was significantly lower in patients undergoing RN
than those undergoing PN during the 3 years follow-up
period. Patients undergoing RN also had a higher risk of
various adverse renal outcomes (i.e., AKI, new-onset
CKD, and ≥25% decline in eGFR after 1 year) compared
to those undergoing PN. Furthermore, RN increased the
risk for deleterious renal outcomes for patients with
small (tumor size ≤4 cm) and moderately (4 cm < tumor
size ≤7 cm) sized RCCs. Therefore, our hypothesis that
RN increases the risk for deleterious renal outcomes forTable 3 Renal outcomes after radical and partial nephrectom
All patients (n = 5
AKI (%)b 290 (52.2)
Stage 1 265 (47.7)
Stage 2 19 (3.4)
Stage 3 6 (1.1)
Transient AKI (%) 173 (31.1)
Persistent AKI (%) 117 (21.0)
New-onset CKD (%)c 190 (36.0)
≥25% decline in eGFR 1 year after surgery (%)d 207 (42.2)
All-cause mortality 42 (7.5)
aP value by age, sex and proteinruia-adjusted logistic regression.
bDefined by Kidney Disease: Improving Global Outcomes guideline.
ceGFR <60 mL/min/1.73 m2 after 3 months postoperatively, calculated using the Ch
deGFR (mL/min/1.73 m2), calculated using the Chronic Kidney Disease-Epidemiology
Abbreviations: eGFR estimated glomerular filtration rate, AKI acute kidney injury, CKacute or chronic state patients with small and moder-
ately sized RCCs is supported by the findings of the
present study.
RN is now recognized as an independent risk factor
for the development of CKD when used as a treatment for
small renal tumors [8,10]. Nevertheless, RN remained the
most common treatment for newly detected small renal
tumors over the last decade. A recent meta-analysis
showed that PN confers a survival advantage and a lower
risk of severe CKD (eGFR <60 mL/min/1.73 m2) after op-
eration for localized renal tumors [17]. Although RN ac-
counts for up to 60% of all nephrectomies in our cohort,
we also found that the incidence of new-onset CKD was
higher in patients undergoing RN than those who were
undergoing PN (55.7% vs. 6.2%, respectively). However,
most studies have investigated the development of CKD at
irregular time points after nephrectomy, and there are lim-
ited data regarding AKI or kidney function decline aftery adjusted for age, sex, and proteinuria
57) RN (n = 339) PN (n = 218) P valuea
237 (70.1) 53 (24.3) <0.001
217 (91.6) 48 (90.1) <0.001
16 (6.7) 3 (5.6) 0.033
4 (1.7) 2 (3.8) 1.000
124 (36.7) 49 (22.5) <0.001
113 (33.4) 4 (1.8) <0.001
177 (55.7) 13 (6.2) <0.001
191 (65.4) 16 (8.1) <0.001
34 (10.0) 8 (3.7) 0.006
ronic Kidney Disease-Epidemiology Collaboration equation.
Collaboration equation.
D chronic kidney disease, RN radical nephrectomy, PN partial nephrectomy.
Table 4 Multivariable logistic regression analysis of renal outcomes categorized by tumor size after nephrectomy
Total cohort
(n = 557)
Tumor size ≤4 cm
(n = 370)
4 cm < tumor size ≤7 cm
(n = 187)
OR (CI 95%) P value OR (CI 95%) P value OR (CI 95%) P value
AKI
Age 0.99 (0.97-1.00) 0.149 0.99 (0.97-1.01) 0.398 0.98 (0.96-1.01) 0.210
Male 3.15 (1.92-5.17) <0.001 3.58 (1.86-6.91) <0.001 2.24 (1.13-5.26) 0.023
BMI 1.11 (1.04-1.19) 0.002 1.09 (1.00-1.19) 0.054 1.14 (1.02-1.27) 0.019
Smoking 1.01 (0.64-1.59) 0.976 0.80 (0.45-1.40) 0.429 1.56 (0.69-3.50) 0.283
Hypertension 1.39 (0.89-2.18) 0.144 1.38 (0.78-2.45) 0.275 1.43 (0.69-2.97) 0.338
Diabetes 0.68 (0.38-1.21) 0.188 0.56 (0.27-1.17) 0.122 0.98 (0.36-2.70) 0.967
Proteinuria 1.00 (0.54-1.85) 0.994 1.08 (0.49-0.34) 0.859 0.87 (0.31-2.48) 0.796
Open surgery 1.06 (0.63-1.79) 0.829 1.04 (0.54-2.01) 0.901 1.15 (0.46-2.85) 0.770
Stage III 0.69 (0.18-2.58) 0.576 0.43 (0.02-8.43) 0.575 0.93 (0.19-4.67) 0.931
Partial nephrectomy 1 [Reference] 1 [Reference] 1 [Reference]
Radical nephrectomy 9.57(6.20-14.8) <0.001 12.8 (7.09-20.7) <0.001 5.49 (1.52-19.9) 0.009
New-onset CKD
Age 1.06 (1.04-1.08) <0.001 1.06 (1.03-1.09) <0.001 1.06 (1.03-1.10) <0.001
Male 1.04 (0.60-1.78) 0.898 0.99 (0.46-2.13) 0.988 1.01(0.45-2.24) 0.988
BMI 1.00 (0.92-1.07) 0.884 0.99 (0.89-1.10) 0.879 0.97 (0.87-1.08) 0.580
Smoking 1.49 (−0.89-2.51) 0.131 1.62 (0.80-3.25) 0.178 1.60 (0.70-3.67) 0.266
Hypertension 0.87 (0.54-1.41) 0.564 0.98 (0.50-1.90) 0.943 0.70 (0.33-1.47) 0.345
Diabetes 1.52 (0.81-2.84) 0.190 0.97 (0.42-2.23) 0.940 3.38 (1.13-10.1) 0.030
Proteinuria 0.93 (0.48-1.78) 0.815 1.08 (0.46-2.52) 0.859 0.81 (0.26-2.54) 0.722
Open surgery 0.95 (0.49-1.83) 0.874 1.31 (0.54-3.18) 0.555 0.57 (0.21-1.54) 0.266
Stage III 0.44 (0.11-1.84) 0.262 1.36 (0.08-24.1) 0.836 0.27( 0.05-1.48) 0.131
Partial nephrectomy 1 [Reference] 1 [Reference] 1 [Reference]
Radical nephrectomy 23.7(11.7-41.0) <0.001 24.9 (11.7-49.7) <0.001 7.03 (1.18-31.3) 0.031
≥25% decline in eGFR 1 year after surgery
Age 1.01 (0.99-1.03) 0.309 1.01 (0.99-1.04) 0.371 1.01 (0.98-1.04) 0.655
Male 1.58 (0.91-2.74) 0.104 1.99 (0.92-4.29) 0.081 1.03 (0.45-2.38) 0.944
BMI 1.05 (0.97-1.13) 0.220 1.02 (0.92-1.13) 0.712 1.06 (0.94-1.19) 0.362
Smoking 1.10 (0.65-1.83) 0.731 0.77 (0.38-1.55) 0.469 1.85 (0.89-4.33) 0.158
Hypertension 0.85 (0.51-1.41) 0.527 0.68 (0.35-1.36) 0.277 1.07 (0.48-2.40) 0.868
Diabetes 1.57 (0.81-3.03) 0.178 1.64 (0.69-3.86) 0.261 1.50 (0.50-4.49) 0.472
Proteinuria 0.99 (0.50-1.96) 0.971 1.24 (0.50-3.07) 0.638 0.95 (0.31-2.95) 0.930
Open surgery 0.57 (0.29-1.12) 0.102 1.12 (0.46-2.74) 0.805 0.24 (0.08-0.73) 0.011
Stage III 0.77 (0.16-3.71) 0.742 0.55 (0.03-10.5) 0.690 0.69 (0.09-5.10) 0.712
Partial nephrectomy 1 [Reference] 1 [Reference] 1 [Reference]
Radical nephrectomy 22.7 (12.7-40.7) <0.001 28.3 (14.3-56.0) <0.001 12.6 (1.45-108.9) 0.022
Adjusted factors include age, sex, systolic blood pressure, diastolic blood pressure, body mass index, history of smoking, hypertension, and diabetes mellitus, urine
protein level, type of surgical procedure, and pathologic stage.
Abbreviations: OR odds ratio, CI confidential interval, AKI acute kidney injury, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, BMI body
mass index.
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AKI was higher in the RN group compared to the PN
group. Interestingly, persistence AKI at discharge was high
as 33.4% in patients after RN, while it was as low as 1.8%in patients after PN. These findings are in accordance with
another study, which conclude that postoperative AKI in
patients with RCC is associated with new-onset CKD after
RN [19]. Researchers of recent studies have showed that
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[20-22]. Furthermore, patients who underwent RN had a
higher risk of ≥25% decline in kidney function after 1 year
than those who underwent PN. Consequently, RN might
have influenced the postoperative acute and long-term
kidney injury in patients with RCC. According to these
changes, PN would be the preferred surgical treatment
modality for treating RCC rather than RN because of the
advantage of preserving renal function after the operation
[23]. The cancer-specific survival for patients with small
renal cortical tumors is >90% across all histological sub-
types and therefore, there is a need for long-term manage-
ment of postoperative complication (i.e., decreased kidney
function) [24].
Complete surgical excision by PN is recommended for
patients with all clinical T1 kidney tumors (i.e., tumor
size <7 cm) based on compelling data demonstrating
that RN is associated with an increased risk of CKD
[25,26]. Interestingly, it has been reported that as the
tumor size decreased, the risk of new-onset CKD in-
creased in patients undergoing RN for RCC [10]. How-
ever, only a few studies have been published regarding
the link between large tumor sizes and decreased kidney
function after RN or PN. In a few retrospective studies,
RN was found to be associated with the development of
CKD in patients treated for renal tumors of 4–7 cm in
size [11,12,27]. In this regard, our findings are consistent
with the idea that compared to PN, RN is associated
with AKI, kidney function decline, and new-onset CKD
in patients with moderate sized renal tumors (i.e., 4 cm ≤
tumor size <7 cm). If technically feasible, PN might en-
able a better preservation of postoperative kidney func-
tion and also prevent the development of AKI or CKD
for patients with tumors that are up to 7 cm in size.
A lower eGFR before surgery would affect the postop-
erative kidney function. Although the preoperative eGFR
was significantly lower in patients undergoing RN than
in those undergoing PN in the total cohort, which might
be due to the fact that RN was performed more fre-
quently in patients with RCC >4 cm in size, there was a
correlation between increased tumor size and decreased
preoperative eGFR [10]. However, there are no signifi-
cant differences in preoperative eGFR between the pa-
tients in the RN and PN groups according to tumor size.
Therefore, the effect of tumor size on preoperative eGFR
would be attenuated when patients were categorized into
the 2 groups by a tumor size >4 cm. Nevertheless, the
RN group showed a greater decline in eGFR than the
PN group during the 3-year postoperative follow-up
period.
According to two retrospective studies, compensatory
hypertrophy in the non-operated healthy kidney occurs
between 7 days and 4 weeks after RN [10,28]. However,
unlike previous reports, we showed that the non-operated healthy kidney experiences an adaptation in
renal function 3 months after RN. Therefore, we should
monitor renal function until at least 3 months after RN
to prevent further renal injury. In addition, a higher re-
sistive index on duplex ultrasonography, which was not
performed in this study, may be helpful for predicting
AKI and CKD progression after surgery [29].
The present study has several limitations. Firstly, our
study was of retrospective nature and therefore, our
findings may be affected by confounding factors or se-
lection bias. Secondly, we could not evaluate the non-
neoplastic kidney disease, which may have had an effect
on kidney function decline in patients with RCC after
nephrectomy. However, there were no differences in co-
morbidities (i.e., prevalence of hypertension and diabetes
that could lead to parenchyma kidney diseases) between
patients undergoing RN and PN in this study. Thirdly,
long-term renal outcomes could not be fully evaluated
despite checking the eGFR at various time points after
the operations.
Despite these limitations, our study had some strengths.
Firstly, we used the recently validated Chronic Kidney Dis-
ease Epidemiology Collaboration equation to calculate the
eGFR, while most previous studies involved the Modifica-
tion of Diet in Renal Disease equation that systematically
underestimates GFR in individuals without known CKD
[30]. Secondly, we evaluated various renal outcomes in-
cluding AKI, CKD, and kidney function decline to deter-
mine the clinical impact of the surgical procedures.
Finally, we collected data regarding the degree of protein-
uria in our patients and included these in our analyses for
adjustment, which may affect overall kidney function.
Conclusions
The risk for the incidence of AKI, new-onset CKD, and
kidney function decline in patients undergoing RN was
higher than that of patients undergoing PN even for
moderately sized RCC tumors. Therefore, PN should be
considered as the surgical treatment of choice for RCCs
up to 7 cm in size, which will allow for the preservation
of renal function postoperatively.
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